Figure 5

FK506 and tat-VIVIT decreased CD68 immunoreactivity in APP/PS1 mice. Twelve-month-old male APP/PS1 mice were treated via subcutaneous delivery for 28 days with no treatment (control), vehicle DMSO, 1 mg/kg/day FK506, 0.5 mg/kg/day VIVIT, or 0.5 mg/kg/day negative control scrambled peptide, VEET (n = 6 to 8/condition). Brains were collected, sectioned, and stained using anti-CD68 antibody and staining intensities were quantified from serial sections from the hippocampus. The optical density values per condition (five conditions), per brain (six to eight brains per condition), and per section (three sections per brain) were obtained, averaged (±SD), and plotted (***p < 0.001).